ADB-CHMINACA
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
1185887-13-1  |
| PubChem (CID) | 68894304 |
| ChemSpider | 48059556 |
| UNII |
SL4C60689M |
| Chemical and physical data | |
| Formula | C21H30N4O2 |
| Molar mass | 370.24 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[1][2] It was identified in cannabinoid blends in Japan in early 2015.[3]
Side Effects
There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.[4][5][6][7][8][9][10][11]
Legal status
As of October 29, 2014 Louisiana placed ADB-CHMINACA into Schedule I by emergency scheduling.[12]
Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014.[13]
ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[14]
The DEA announced its intent to place ADB-CHMINACA into Schedule I of the USA Controlled Substances Act on September 16, 2015.[15]
ADB-CHMINACA is illegal in Switzerland as of December 2015.[16]
See also
References
- ↑ "MAB-CHMINACA". Cayman Chemical. Retrieved 16 June 2015.
- ↑ "Patent WO/2009/106980 - Indazole derivatives".
- ↑ Amin Wurita; Koutaro Hasegawa; Kayoko Minakata; Kunio Gonmori; Hideki Nozawa; Itaru Yamagishi; Kanako Watanabe; Osamu Suzuki (July 2015). "Identification and quantitation of 5-fluoro-ADB-PINACA and MAB-CHMINACA in dubious herbal products". Forensic Toxicology. 33 (2): 213–220. doi:10.1007/s11419-015-0264-y.
- ↑ Koutaro Hasegawa; Amin Wurita; Kayoko Minakata; Kunio Gonmori; Hideki Nozawa; Itaru Yamagishi; Kanako Watanabe; Osamu Suzuki (July 2015). "Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver". Forensic Toxicology. 33 (2): 380–387. doi:10.1007/s11419-015-0272-y.
- ↑ Alan Schwarz (24 April 2015). "Potent 'Spice' Drug Fuels Rise in Visits to Emergency Room". The New York Times. Retrieved 29 June 2015.
- ↑ "American Association of Poison Control Centers Issues Warning About Reemerging Synthetic Drugs". American Association of Poison Control Centers. 23 April 2015. Retrieved 29 June 2015.
- ↑ "Synthetic cannabinoid users can exhibit bizarre and violent behaviors, hospitalizations after use increase in Alabama over past week" (PDF). Alabama Department of Public Health. 11 May 2015. Retrieved 29 June 2015.
- ↑ "Todesfälle in Zusammenhang mit ADB-CHMINACA". Drug Scouts. 7 May 2015. Retrieved 29 June 2015.
- ↑ Jordan Trecki; Roy R. Gerona; Michael D. Schwartz (July 2015). "Synthetic Cannabinoid–Related Illnesses and Deaths". New England Journal of Medicine. 373 (2): 103–107. doi:10.1056/NEJMp1505328. PMID 26154784.
- ↑ Dave Collins (8 May 2015). "There's Been A Sudden, Alarming Spike In Hospitalizations Caused By Synthetic Marijuana". Huffington Post. Retrieved 8 August 2015.
- ↑ Piotr Adamowicz, Joanna Gieroń (May 2016). "Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA". Clinical Toxicology: 1–5. doi:10.1080/15563650.2016.1190016. PMID 27227269.
- ↑ "Gov. Jindal and State Officials Ban New Synthetic Marijuana Compound". Retrieved 16 June 2015.
- ↑ "Cannabinoider föreslås bli klassade som hälsofarlig vara". Folkhälsomyndigheten. Retrieved 29 June 2015.
- ↑ "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Retrieved 24 July 2015.
- ↑ "Schedules of Controlled Substances: Temporary Placement of the Synthetic Cannabinoid MAB-CHMINACA Into Schedule I". Drug Enforcement Administration. 16 September 2015. Retrieved 16 September 2015.
- ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien". Der Bundesrat.